The anaplastic lymphoma kinase (ALK) fusion oncogene is observed in 3%–5% of non-
small cell lung cancer (NSCLC). Crizotinib and ceritinib, a next-generation ALK tyrosine …

The treatment of patients with advanced non-small cell lung cancer (NSCLC) harbouring
chromosomal rearrangements of ALK (anaplastic lymphoma kinase) was revolutionized by …

Crizotinib as the first-generation ALK inhibitor has shown significant activity in ALK-mutated
non-small cell lung cancer (NSCLC). Second-and third-generation ALK inhibitors are …

Background Conventional cytotoxic chemotherapy (CCC) is the backbone of non-small-cell
lung cancer (NSCLC) treatment since decades and still represents a key element of the …

Introduction. For patients with non-small cell lung cancer (NSCLC) to benefit from ALK
inhibitors, sensitive and specific detection of ALK genomic rearrangements is needed. ALK …

Although gene fusions have been recognized as important drivers of cancer for decades,
our understanding of the prevalence and function of gene fusions has been revolutionized …

ABSTRACT Programmed cell death (PD)-1/PD-1 ligand-1 (PD-L1)-targeted therapy has
emerged as a promising therapeutic strategy for lung cancer. However, whether EML4-ALK …

Lung cancer remains the leading cause of cancer-related death worldwide. NSCLC
accounts for more than 85% of all lung cancers, and the prognosis for advanced-stage …

Introduction BRAF (v-Raf murine sarcoma viral oncogene homolog B) mutations are
identified in approximately 2% of non-small cell lung cancer (NSCLC). Because of the rarity …

Advances in deep genomic sequencing have identified a spectrum of cancer-specific
passenger and driver aberrations. Clones with driver anomalies are believed to be positively …